Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study
Our modelling estimates that the population impact of new TB vaccines may depend on efficacy against infectious asymptomatic disease. TB vaccine trials should include analyses of participant sputum samples (collected during or at the end of trials and analysed at the end of trials) to enable better estimates of the potential value of new TB vaccines against infectious asymptomatic disease.
Authors
- Roel Bakker (ORCID: https://orcid.org/0000-0002-1958-0944)
- Gavin Churchyard (ORCID: https://orcid.org/0000-0002-4269-3699)
- Mave
- Hira Tanvir (ORCID: https://orcid.org/0009-0006-5358-6932)
- Tomos O. Prys-Jones
- Mark Hatherill
- Rein M. G. J. Houben
- Tom Sumner
- Kirankumar Rade
- Richard G. White
- Rebecca A. Clark
- Katherine C. Horton
Institutions
- Johns Hopkins University (US)
- University of Cape Town (ZA)
- University of the Witwatersrand (ZA)
- Vanderbilt University (US)
- B. J. Medical College & Sassoon Hospital (IN)
- TuBerculosis Vaccine Initiative (NL)
- London School of Hygiene & Tropical Medicine (GB)
- South African Tuberculosis Vaccine Initiative (ZA)
- Aurum Institute (ZA)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1371/journal.pmed.1004595
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00